Estimated antiretroviral therapy coverage among people living with HIV in SEAR
SEAR: Estimated antiretroviral therapy coverage among people living with HIV was 22.0% in 2025. ◆ Volatile
Estimated antiretroviral therapy coverage among people living with HIV in SEAR, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, estimated antiretroviral therapy coverage among people living with hiv in SEAR stood at 22.0%. That is the highest value across all 26 years on record.
Compared with earlier readings it is up 4.8% on the previous year and up 69.2% over ten years.
Over the whole period, estimated antiretroviral therapy coverage among people living with hiv in SEAR peaked at 22.0% in 2025 and was at its lowest, 0.0%, in 2000.
The series is highly variable year to year, so single readings are best treated with caution.
Estimated antiretroviral therapy coverage among people living with HIV in SEAR, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 1.0% | — |
| 2004 | 1.0% | +0.0% |
| 2005 | 2.0% | +100.0% |
| 2006 | 3.0% | +50.0% |
| 2007 | 4.0% | +33.3% |
| 2008 | 5.0% | +25.0% |
| 2009 | 6.0% | +20.0% |
| 2010 | 7.0% | +16.7% |
| 2011 | 8.0% | +14.3% |
| 2012 | 9.0% | +12.5% |
| 2013 | 10.0% | +11.1% |
| 2014 | 11.0% | +10.0% |
| 2015 | 13.0% | +18.2% |
| 2016 | 14.0% | +7.7% |
| 2017 | 16.0% | +14.3% |
| 2018 | 17.0% | +6.2% |
| 2019 | 18.0% | +5.9% |
| 2020 | 19.0% | +5.6% |
| 2021 | 19.0% | +0.0% |
| 2022 | 20.0% | +5.3% |
| 2023 | 21.0% | +5.0% |
| 2024 | 21.0% | +0.0% |
| 2025 | 22.0% | +4.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 2.2% | 0.0% | 6.0% | 10 |
| 2010s | 12.3% | 7.0% | 18.0% | 10 |
| 2020s | 20.3% | 19.0% | 22.0% | 6 |
Countries ranked near SEAR
More health data for SEAR
- Mortality rate among children ages 5 to 9 years 1.94 (2024)
- Population with primary reliance on polluting fuels and technologies 493.79 (2023)
- Population with primary reliance on fuels and technologies for 470.67 (2023)
- Proportion of population with primary reliance on fuels and 37.5% (2023)
- Prevalence of diabetes, crude 20.36 (2022)
- Diphtheria tetanus toxoid and pertussis first-dose (DTP1) 96.0% (2025)
- Measles-containing-vaccine first-dose (MCV1) immunization coverage 96.0% (2025)
- New HIV infections 0.1 (2025)
- BCG immunization coverage among 1-year-olds (%) 91.0% (2025)
- Mean HDL cholesterol, crude 1.1 (2018)
Frequently asked questions
- What is estimated antiretroviral therapy coverage among people living with hiv in SEAR?
- Estimated antiretroviral therapy coverage among people living with hiv in SEAR was 22.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest estimated antiretroviral therapy coverage among people living with hiv recorded in SEAR?
- The highest recorded value was 22.0% in 2025.
- What is the lowest estimated antiretroviral therapy coverage among people living with hiv recorded in SEAR?
- The lowest recorded value was 0.0% in 2000.
- How does SEAR rank for estimated antiretroviral therapy coverage among people living with hiv?
- SEAR ranks 12th out of 13 groups with data for 2025.
- Is estimated antiretroviral therapy coverage among people living with hiv rising or falling in SEAR?
- Over the last ten years it is up 69.2%. The long-run trend across the full record is volatile.
- Where does this SEAR data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).